Michael J Droller, MD
- PROFESSOR | Urology
- PROFESSOR | Oncological Sciences
Michael J. Droller, M.D., is a board certified urologist who received his medical degree cum laude from Harvard Medical School. He completed his internship in internal medicine at the Albert Einstein College of Medicine, went on to begin a surgical residency at the Peter Bent Brigham Hospital in Boston, and then took a position in the US Public Health Service at the National Institutes of Health as a Clinical Associate in the National Institute of Arthritis and Metabolic Diseases to pursue clinical and laboratory investigations. He completed his urology residency at Stanford University Medical Center, spent a year in immunologic research in the Department of Immunology at the University of Stockholm, and then joined the faculty in the Departments of Urology and Oncology at the Johns Hopkins Hospital and School of Medicine. Dr. Droller came to Mount Sinai as Professor and Chairman of the Department of Urology in 1984, serving in that capacity for 19 years and becoming the Katherine and Clifford Goldsmith Professor of Urology (1998) and Professor of Oncology.
Dr. Droller's clinical interests center on urological cancers, with a major focus on bladder cancer and prostate cancer. In pursuing these areas both clincally and in the laboratory, he has also been extensively involved in teaching and communicating to professional colleagues and to the public on these topics, through serving in several major leadership positions for a number of major organizations and professional journals. He founded the Prostate Health Center for the Department in 1999. He is currently Editor-in-Chief of Urologic Oncology: Seminars and Original Investigations, which is the official journal of the Society of Urologic Oncology. He is also Associate Editor of the Journal of Urology, the official journal of the American Urological Association. He has also served as Chairman of the Medical Advisory Council for the American Foundation for Urological Diseases, having served as co-Chair for the Bladder Health Council of that organization for 12 years. He has been President and on the Executive Committee of the Society of Urologic Oncology, the Urological Research Society, the New York Section of the American Urological Association, and the New York State Urological Society, and has served as Chairman of the Section of Urology of the New York Academy of Medicine. In addition, he is a member of 15 professional societies and on the editorial board of eight professional journals. His government service has included terms as consultant to the Island Peer Review Organization on the Standards Norms and Criteria Committee and the New York State Department of Health Task Force on Clinical Guidelines and Medical Terminology Assessment.
American Board of Urology
- Benign Prostatic Hyperplasia
- Bladder Cancer
- Kidney Cancer
MD, Harvard Medical School
Internship, Internal Medicine, Albert Einstein College of Medicine
Residency, Surgery, Brigham and Women's Hospital
Residency, Urology, Stanford University Hospital
Legends in Urology
Career Achievement Award
Doctor of Medicine Honoris Causa
Alpha Omega Alpha
Phi Beta Kappa
Sigma Xi Research Honor Society
Droller MJ. Advanced Bladder Cancer. Philadelphia, Pennsylvania, Urologic Clinics N. America, W.B.Saunders; 1992.
Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. European urology 2016 Jul; 70(1).
Smith JA, Zietman A, Klein E, Droller MJ, Dasgupta P, Catto J, Smith JA. Stage Grouping. The Journal of urology 2016 Jun; 195(6).
Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Consensus guidelines for reporting prostate cancer Gleason Grade. BJU international 2016 Jun; 117(6).
Grossman HB, Gomella L, Fradet Y, Droller MJ, Presti J, Ritenovr C, Nseyo U, Morales A. A phase III multicenter comparison of hexaminolevulinate (HAL) flourescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J. Urol. 2007; 178: 622-667.
Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Urology 2016 Jul; 93.
Droller MJ. Urothelial Tumors. Hamilton Canada, BC Decker, Inc; 2004.
Droller MJ. Bladder Cancer: Current Diagnosis and Treatment. Totowa, New Jersey, Humana Press; 2001.
Shemtov MM, Chang DL C, Kong L, Shu WP, Sassaroli M, Droller MJ, Liu BC S. LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: Possible mechanism of BCG therapy. J Urol 1995; 154: 269-271.